This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Charles River Laboratories International, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260 MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $270 From $280 MT
Jefferies Adjusts Price Target on Charles River Laboratories International to $226 From $235 MT
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300 MT
Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282 MT
Transcript : Charles River Laboratories International, Inc., Q1 2024 Earnings Call, May 09, 2024
Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance MT
Charles River Laboratories International, Inc. Reports Impairment Charges for the First Quarter Ended March 30, 2024 CI
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024 CI
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q1 Adjusted EPS $2.27 MT
Stocks Down Pre-Bell Ahead of Latest Earnings Results; Asia, Europe Churn MT
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Posts Q1 Revenue $1.01B MT
(CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Expects Fiscal Year 2024 Adjusted EPS Range $10.90 - $11.40 MT
Charles River Laboratories International, Inc. Revises Financial Guidance for 2024 CI
China trade heats up, UK rates in view RE
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI
Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission CI
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing CI
Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278 MT
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology CI
Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies MT
Charles River Laboratories International, Inc. Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics CI
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus MT
Charles River Laboratories International, Inc. and Ship of Theseus Announces Good Manufacturing Practice Plasmid DNA Contract Development and Manufacturing Organization Agreement CI
Chart Charles River Laboratories International, Inc.
More charts
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
217.2 USD
Average target price
265.6 USD
Spread / Average Target
+22.28%
Consensus
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. News Charles River Laboratories International, Inc.
  5. Deutsche Bank Raises Charles River Laboratories International Price Target to $275 From $245, Maintains Buy Rating